fda glp-1 compounding crackdown october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Warns on Certain Forms
Description
And unlike ICER, it avoids using discriminatory methods for assessing value such as quality-adjusted life years (QALYs), which tend to favor treatments that help healthier patients

& Volpe, M
DOI: 10.1172/jci.insight.127994

The independent and combined hepatic effects of GIP and GLP-1 have been explored in preclinical studies and potential beneficial effects on NAFLD/NASH have been demonstrated [6, 62,63,64,65,66]

GLP-1 receptor agonists target areas of the brain that regulate hunger and appetite
Bottom line: Muscle retention during weight loss is driven by training, not the medication
